Celsus, Volution Immuno Pharma ink Agreement to Create Orphan Disease Company


McDermott UK lawyers served as legal counsel to Volution Immuno Pharmaceuticals SA in a transaction whereby privately held Volution will become a wholly-owned subsidiary of Celsus Therapeutics. The combined company will focus on development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Read the full article